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Summary
For analysis of multidrug resistance, a major barrier to effective cancer chemotherapy, we profiled mRNA expression of
the 48 known human ABC transporters in 60 diverse cancer cell lines (the NCI-60) used by the National Cancer Institute
to screen for anticancer activity. The use of real-time RT-PCR avoided artifacts commonly encountered with microarray
technologies. By correlating the results with the growth inhibitory profiles of 1,429 candidate anticancer drugs tested
against the cells, we identified which transporters are more likely than others to confer resistance to which agents.
Unexpectedly, we also found and validated compounds whose activity is potentiated, rather than antagonized, by the
MDR1 multidrug transporter. Such compounds may serve as leads for development.
Introduction the functions of most members of the family. Given the high
degree of similarity of ABC sequences, however, it seems plausi-
ble that additional members may also be drug exporters andThe ABC (ATP binding cassette) family of membrane transport
proteins includes the best-known mediators of resistance to may thus be associated with decreased sensitivity of cancer
cells to chemotherapy. To explore that proposition, we wantedanticancer drugs. In particular, MDR (multidrug resistance)
pumps ABCB1 (MDR1-P-gp), ABCC1-MRP1, and ABCG2-MXR to characterize ABC gene expression in a set of cancer cells
whose responses to a large number of compounds are known(Gottesman et al., 2002; Cole et al., 1992; Borst et al., 2000;
Deeley and Cole, 1997; Litman et al., 2001) actively extrude and whose molecular characteristics have been cataloged. The
natural choice was a panel of 60 human cancer cell lines (themany types of drugs from cancer cells, thereby conferring resis-
tance to those agents. More broadly, the ABC transporters ap- NCI-60) used by the Developmental Therapeutics Program
(DTP) of the National Cancer Institute (NCI) to screen 100,000pear to have evolved to defend the cell through recognition and
energy-dependent removal of a large variety of natural toxic chemical compounds since 1990. Included among the 60 are
leukemias, melanomas, and cancers of ovarian, breast, pros-agents (Sarkadi et al., 1996). Their functional significance is
suggested by the observation that they form one of the largest tate, lung, renal, colon, and central nervous system origin. Pat-
terns of drug activity across the cell lines and patterns of cellprotein families, found in various cellular membranes of organ-
isms from bacteria to mammals. Based on sequence homology, sensitivity across the set of tested drugs have been shown
to contain detailed information on mechanisms of action and48 different ABC transporters (grouped into seven subfamilies
ranging from A to G) have been defined in the human genome. resistance (Paull et al., 1989; Weinstein et al., 1992). In addition
to this pharmacological characterization, the NCI-60 cells haveTheir functions range from export of cholesterol (ABCA1) to
regulation of chloride current (ABCC7-CFTR), and they play been more extensively profiled at the DNA, mRNA, protein,
and functional levels than any other set of cells in existence.roles in the absorption, distribution, and excretion of pharmaco-
logical compounds. Therefore, if we were to measure their expression of ABC trans-
porters, it would be possible to link ABC transport function toDespite these generalizations, relatively little is known about
S I G N I F I C A N C E
Multidrug resistance of tumors is frequently associated with decreased cellular accumulation of anticancer drugs and elevated
expression of ABC transporters such as MDR1. At present, relatively little is known about the substrate specificities of most ABC
transporters. Here, we present a pharmacogenomic approach, in which we correlate expression profiles of all 48 human ABC
transporters with patterns of drug activity in the NCI-60 cell lines. The findings are used to identify candidate substrates for several
ABC transporters, as well as compounds whose toxicities are potentiated by ABCB1-MDR1. The gene expression database will serve
as a high-quality “time capsule” that can be mined to generate new hypotheses and to illuminate additional features of ABC
transporters and their functional relationships with other molecules.
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a variety of other molecular, physiological, and pharmacological of origin is moderate (see Supplemental Table S2), as indicated
by a  statistic of 0.46 (with two-tailed 95% confidence intervalfeatures of the cells.
We wished to focus, in particular, on the relationship be- 0.33–0.60). Interestingly, the two lumenal, estrogen receptor-
positive breast lines (T47D and MCF7) cluster together.tween ABC expression levels and sensitivity to drugs or drug
candidates, asking which of the transporters do (and which do This database provides valuable information on the expres-
sion patterns of both known and currently uncharacterized ABCnot) confer resistance or sensitivity to various classes of agents.
Previous transcript expression profiling of the NCI-60 using transporters. Some of them are expressed ubiquitously (e.g.,
ABCC1), whereas others are selectively expressed in particularcDNA arrays of 9000 elements (Scherf et al., 2000) and Affy-
metrix Hu6800 oligonucleotide chips (Staunton et al., 2001) cell types (e.g., ABCB5 in melanoma-derived cells; see inset in
Figure 1 and Supplemental Table S3). Langmann et al. (2003)proved useful for identification of patterns and molecular bio-
markers. However, those studies had three major limitations found high expression of ABCA2 in brain, ABCA3 in lung, and
ABCB1 and ABCC4 in kidney. When analyzed by Monte Carlowith reference to the ABC transporters: (1) only 15 and 11 of
the 48 transporters were represented in the cDNA and oligonu- permutation t test, our data show that ABCA2 is ubiquitously
expressed throughout the 60 lines (p  0.61 for each of thecleotide arrays, respectively; the total combined coverage was
only 17 of 48, and the mean correlation between the two sets nine tissues of origin), whereas ABCA3 is selectively expressed
(p  0.039) in H522M, A549, and EKVX (all of them lung cancerfor the 9 transporters represented in both was only 0.43; (2)
in part because of limited sensitivity, 64.2% and 58.5% of the lines). ABCB1 is indeed selectively expressed in the renal cancer
cell lines (p  0.0059). However, ABCC4 is only moderatelyvalues were undetectable above background for the cDNA and
oligonucleotide arrays, respectively; and (3) crosshybridization expressed in those cells (p  0.145 for each of the nine tissues
of origin). This apparent discrepancy with respect to the resultsamong close family members could be expected, especially
with the cDNA arrays, but also with the oligonucleotide arrays of Langman et al. may be due to heterogeneity of the human
tissue samples used in that study, or may reflect distinctiveinsofar as they were not designed with central focus on the
ABC transporters. Since reproducible, quantitative correlations characteristics of the cancer cells. The distribution of ABC trans-
porters on the gene dendrogram appears to be independent ofbetween expression and sensitivity were required for our study,
we chose to measure transcript expression by the “gold stan- sequence-homology categories. ABCB2 and ABCB3, known
to function as heterodimeric components of the ER transportdard” method, quantitative real-time RT-PCR, rather than the
less sensitive, less specific microarray technology. Finding such system for peptide antigen presentation, are found in different
clusters, suggesting that their reported coordinate expressioncorrelations (and confirming them in follow-up studies) demon-
strates the important role of ABC transporters in the drug resis- is disrupted in the cancer cells. Conversely, ABCG5 and ABCG8,
which also form a heterodimer, show the expected concordancetance of cancer cells. One striking result was the identification
of at least one compound whose toxicity appears to be potenti- in expression pattern across the 60 cells (see Figure 1).
ated, rather than antagonized, by ABCB1 (MDR1).
Correlation of ABC transporter mRNA levels
with drug resistanceResults and discussion
In a previous study using cDNA microarrays, the 60 cell lines
were found to cluster reasonably well by tissue of origin on theForty-eight ABC proteins are coded by the human genome
(see http://nutrigene.4t.com/humanabc.htm for a comprehen- basis of expression patterns determined for a broad range of
genes, but they did not cluster as well on the basis of patternssive database). Figure 1 shows a clustered image map (“heat
map”) (Weinstein et al., 1997) that offers a visual summary of of drug sensitivity (Scherf et al., 2000). Furthermore, there was
only a modest correspondence between the two clusterings.the patterns of ABC transporter expression across the 60 cell
lines. The complete RT-PCR results on the 48 ABC transporters Hence, cell clusters in the present study that appear similar for
both ABC transporter expression and drug activity patterns are(47 determined in this work and one previously reported [Prades
et al., 2002]) are presented in Supplemental Table S1 at http:// particularly interesting. Clusters such as that consisting of
ACHN, UO-31, HCT15, and NCI-ADR-RES fall into that cate-www.cancercell.org/cgi/content/full/6/2/129/DC1. A 49th ABC
gene, ABCC13, is predicted to encode a nonfunctional protein gory. Not surprisingly, ABCB1 (i.e., MDR1) is highly expressed
in those cells.(Yabuuchi et al., 2002) and therefore is not included in this study.
Quantitative analysis showed that the pattern of expression is Since ABCB1 (MDR1-Pgp) extrudes molecules from the cell,
the activity patterns of its substrates across the 60 cell linesmost characteristic of tissue of origin for melanoma (9 of the
10 melanoma cells cluster together on the dendrogram). The are expected to be negatively correlated with its pattern of
expression (Shoemaker, 2000; Lee et al., 1994). Figure 2 indi-one melanoma line not found in the melanoma cluster (LOX-
IMVI) is amelanotic and undifferentiated and has been shown cates that such is indeed the case for a set of 118 compounds
with putatively known mechanisms of action (Weinstein et al.,to lack transcripts characteristic of melanoma (Stinson et al.,
1992). MDA-MB435 and MDA-N were originally thought to be 1992). Reported substrates (e.g., geldanamycin, paclitaxel and
its analogs, doxorubicin and vinblastine, and bisantrene [Lee etfrom breast cancer, but their appearance within the melanoma
cluster is consistent with strong molecular profile evidence that al., 1994]), indicated by blue bars, show striking inverse correla-
tions, whereas compounds not transported by MDR1 (e.g., hy-they are melanoma-derived or at least melanoma-like (Scherf
et al., 2000; Ellison et al., 2002; Ross et al., 2000). MDA-N is droxyurea, camptothecins, methotrexate, and 5-fluorouracil) are
invariably found to be noncorrelated or positively correlated (redan ERBB2 transfectant of MDA-MB435. CNS (5/6), renal (5/8),
and ovarian (4/6) cells tend to form clusters, whereas the leuke- bars). Of the 118 compounds, only two inversely correlated
drugs, an anthrapyrazole-derivative (NSC 355644, r  0.36)mia, colon, lung, breast, and prostate cancer cell lines do not
cluster well by tissue of origin. Overall, the coherence by tissue and Baker’s soluble antifol (NSC 139105, r  0.3), have not
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Figure 1. ABC transporter gene expression in the NCI-60 human cancer cell panel
The clustered image map shows patterns of gene expression assessed by real-time RT-PCR. Red and blue indicate high and low expression, respectively.
The hierarchical clustering on each axis was done using the average-linkage algorithm with 1r as the distance metric, where r is the Pearson’s correlation
coefficient, after subtracting row and column means. The inset highlights ABC transporters characteristically expressed in melanoma cells. For more details,
see Supplemental Table S3.
previously been established as MDR1 substrates (black bars). distribution of ABCB1 was heavily right-skewed (i.e., a small
number of the cell lines expressed high levels of ABCB1 tran-However, resistance to Baker’s antifol is reversed by verapamil,
a potent inhibitor of MDR1 transport, suggesting that it is indeed script), we were concerned that the correlations obtained might
be based on the relationship of drug activity to MDR1 expressionan MDR1 substrate (Gupta et al., 1988).
To identify additional compounds that show significant in- in only a subset of the cell types. Therefore, we also computed
bootstrap distributions (based on 10,000 bootstrap samples) ofverse correlation with the expression of ABCB1, we extended
the analysis to a larger data set containing the activity patterns all correlations to obtain estimates of variability and confidence
intervals with stringent significance levels. The 18 compoundsof 1,429 compounds (Scherf et al., 2000). Since the measured
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These results support the idea that correlation of ABCB1
expression with activity patterns in the 60 cell lines can be used
to identify potential ABCB1 substrates among the 100,000
compounds tested at the NCI (Alvarez et al., 1995; Izquierdo et
al., 1996; Bates et al., 1994; Wu et al., 1992). The chemical
properties of inversely correlated compounds may also help
define the “common pharmacophore” of the structurally dissimi-
lar MDR1 substrates (Scala et al., 1997; Pajeva and Wiese,
2002; Blower et al., 2002).
ABC proteins transport a wide variety of compounds through
the lipid bilayer, and identification of transported molecules
should help us understand the physiological mechanisms and
specificities of the transporters. To identify which ABC trans-
porters and substrates may play roles in drug resistance of
cancer cells, we calculated Pearson’s correlation coefficients
for a total of 68,592 relationships (48 genes 1429 compounds;
Supplemental Table S5) using bootstrap analysis with 10,000
iterations. The analysis yielded 131 highly inverse-correlated
gene-drug pairs (Supplemental Table S6), sufficiently highly cor-Figure 2. Relationship between drug sensitivity and ABCB1 expression in the
related in the negative sense that none of their 10,000 bootstrapNCI-60 for a set of 118 drugs of putatively known mechanism of action
samples were positively correlated. This list suggests that sev-Blue bars indicate known ABCB1 substrates; red bars indicate compounds
eral ABC transporters of unknown function can, in fact, influenceshown in previous studies not to be substrates of ABCB1; black bars indicate
compounds for which data were not available from the literature. The drug response of cells to treatment. Assuming functional relationship,
names listed at the top and bottom are commonly used, representative the compounds are predicted to be substrates of the respective
agents from the classes shown by red and blue bars.
ABC transporters. To verify this hypothesis, we performed inde-
pendent followup experiments in defined systems for the most
interesting correlative findings. As examples, we will describe
here the results for two transporter drug pairs, one involvingthat survived this statistical screening share structural features
ABCC2-MRP2, the other involving ABCC11.(large size, polyaromatic backbone, amphipathic character) with
The ABCC (MRP) subfamily is comprised of nine membersthe well-known MDR1 substrates (Rabow et al., 2002; Supple-
that transport structurally diverse lipophilic anions and functionmental Figure S1 at http://www.cancercell.org/cgi/content/
as drug efflux pumps (Kruh and Belinsky, 2003). ABCC2-MRP2full/6/2/129/DC1). NSC 328426 (phyllanthoside), NSC 259968
is a canalicular efflux pump with a role in the hepatobiliary(Bouvardin), and NSC 156625 (Coralyne) have been tested in
excretion of bilirubin glucuronide as well as numerous pharma-various laboratories and shown to interact with MDR1 (Lee et
ceuticals. ABCC11, a recently identified member of the super-al., 1994; Gupta et al., 1988). The rest have not previously been
family, has been shown to mediate the ATP-dependent trans-implicated in MDR1-mediated resistance.
port of cyclic nucleotides and confer resistance to certain
nucleotide analogs (Guo et al., 2003). Of the 1429 compoundsEvidence that correlations predict drug resistance
analyzed in this study, 14 were shown by the stringent bootstrapdue to ABC transporters
criterion described above to be less active in cells that ex-To test whether our approach using the NCI-60 does, in fact,
pressed large amounts of ABCC2. One of these compoundsidentify new substrates, we used the MTT assay to test all top-
was available from DTP for followup testing (Figure 4A). Onescoring compounds that were available from DTP for follow-up
compound was less active in the presence of large amounts ofexperiments. KB-3-1, a human carcinoma cell line, and KB-V1,
ABCC11 (Figure 4C, Supplemental Figure S1, and Supplementala multidrug resistant derivative of KB-3-1 that overexpresses
Table S6). To verify whether these highly significant negativeMDR1-P-gp (Shen et al., 1986), were used for the tests. Figure
correlations indicate functional relationships, in which ABCC23 shows a typical result. When compared with the parental line,
and ABCC11 protect the cells by exporting the related com-KB-V1 cells proved resistant to NSC 363997. PSC 833, an
pounds, we compared control cells with ABCC2-transfectedMDR1 antagonist, reversed the resistance, providing evidence
or ABCC11-transfected derivatives in MTT assays. In sharpthat the observed resistance was linked to P-gp function. Fur-
contrast to the control (sham-transfected) cells, the ABCC2-ther experiments showed that KB-V1 cells were 30- to 300-fold
overexpressing MDCKII cells proved extremely resistant to NSCless sensitive than KB-3-1 cells to all 6 compounds available
641281, reinforcing the suggestion that NSC 641281 is anfor study. This resistance of KB-V1 cells was invariably reversible
ABCC2-MRP2 substrate (Figure 4B). Similarly, ABCC11-trans-by PSC 833. The intrinsic fluorescence of one of the com-
fected LLC-PK1 cells were 2- to 3-fold more resistant to NSCpounds, NSC 634791, allowed us to measure the effect of MDR1
671136 than were control, sham-transfected cells (Figure 4D),activity on its export from cells. Following incubation with NSC
suggesting that ABCC11-mediated resistance can extend to634791 for 10 min at 37C, MDR1-positive cells contained less
types of compounds other than nucleotide analogs.of the fluorescent compound than did the parental KB-3-1 cell
The real-time RT-PCR database and analytical approachline (Figure 3). The decreased accumulation was completely
presented here thus provide an unbiased method for dis-reversible by addition of PSC 833 (which had no effect on the
covering the substrate specificities of known, as well as yetparental cells), further corroborating the hypothesis that NSC
634791 is an MDR1 substrate. uncharacterized, members of the superfamily. Activity profiles
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Figure 3. Verification of novel ABCB1 substrates
by studies following up on NCI-60 correlations
A: Scatter plot showing the correlation (r) of
ABCB1 expression with sensitivity of the 60 cells
to NSC 363997 (r0.59; 99.99% two-tailed boot-
strap confidence interval 0.8488 to 0.1130).
B: MTT assay dose-response curves for treatment
of KB-3-1 parental cancer cells and the selected
resistant variant KBV1 with increasing concentra-
tions of NSC 363997. The dashed lines indicate
the same, but in the presence of 2 M inhibitor
PSC 833 (for KB-3-1, the solid and dashed lines
overlap). Values are means 	 SEM for represen-
tative experiments performed in triplicate.
C: Summary of further, analogous cytotoxicity
assays performed using the other five available
compounds. Concentrations resulting in 50% cell
death (IC50) in the absence and presence (val-
ues in parentheses) of 2 M PSC 833 are shown
in moles/liter. The effect of the MDR1-P-gp inhibitor PSC 833 on IC50 values in KB-V1 cells is expressed as a dose modifying factor, DMF  (IC50/[IC50]PSC833),
where (IC50)PSC833 is the value obtained in the presence of the inhibitor.
D: Accumulation of the intrinsically fluorescent compound NSC 634791 in MDR1-overexpressing KB-V1 cells. Representative histograms show the green
fluorescence of cells after incubation with 1.74 M NSC 634791 for 10 min at 37C in the presence (gray) or absence (black) of 2 M PSC 833.
of the 18 ABCB1 substrates were very strongly correlated with ABCD1-expression are therefore likely to be positively corre-
lated with ABCB1 expression (Supplemental Table S5).expression of the transporter. In contrast, the other two mole-
cules considered to be “MDR transporters,” ABCC1 (MRP1)
and ABCG2 (MXR or BCRP), were more weakly correlated with Positive correlations identify compounds
potentiated by ABCB1a smaller number of compounds, which did not include known
substrates. The lack of the expected correlations may partially The positive correlation between activity and ABCB1 expression
for some of the compounds in Supplemental Table S5 suggestsbe explained by the statistical limitations of the correlative ap-
proach: the sample size (n  60), the experimental uncertainty, that those compounds can inhibit growth of the cancer cells
more strongly if MDR1 is overexpressed. For some transporters,and the fact that multiple tests of significance are being done
simultaneously may contribute to false negative predictions including MDR1, several high positive correlations between
gene expression and drug sensitivity are higher than would be(hence, the “multiple testing” corrections we describe in the
text and Experimental Procedures). There are also biological expected by random sampling from a distribution of no real
underlying correlations (in the case of MDR1, for the top 10limitations: first, as is the case for almost all transcript profiling
studies, there remains uncertainty about the relationship be- positive correlations, the Benjamini-Hochberg procedure [Reiner
et al., 2003] estimates on average 3 false positive predictions).tween mRNA and protein expression, and the relationship of
both to function. As indicated in Supplemental Table S8 and Thus the toxicity of at least some of the compounds increases
systematically with higher MDR1 expression in the NCI-60. ToSupplemental Figure S2 at http://www.cancercell.org/cgi/content/
full/6/2/129/DC1, a comparison of the mRNA and protein ex- investigate that possibility, we used the MTT assay and the KB-
3-1/KB-V1 cell pair to test the top-scoring compound that waspression profiles for ABCB1 and ABCG2, respectively, indicates
that, at least for those two transporters, the real-time RT-PCR available from DTP (Figure 5A). Figure 5B shows that KB-V1
cells are 4- to 5-fold more sensitive than the parental KB-3-1.and protein expression data correlate quite well. Second, corre-
lation does not imply causality. Third, there might be functionally The finding that PSC 833 completely reversed sensitivity of KB-
V1 cells to NSC 73306 strongly suggests that the increasedrelevant differences between the RNA messages that are not
detected by RT-PCR measurements. That is, the 60 cells may sensitivity is due to the function of MDR1, not to other, nonspe-
cific properties of the KB-V1 cells.contain splice variants or SNPs that influence the substrate
specificities of the transporters (Imai et al., 2002; Honjo et al., To substantiate further that the observed potentiation of
NSC 73306 was not due to nonspecific factors arising during2002). Fourth, cofactors (e.g., conjugating enzymes) or trans-
porters (e.g., ABCC1) may be expressed discordantly in the 60 the generation of KB-V1, we repeated the MTT assays using
HeLa-transfectants in which human MDR1 is under tetracyclinecells. Fifth, the ubiquitous and consistent expression of certain
ABC transporters (e.g., ABCC1) makes it difficult to detect func- control. In these cells, addition of tetracycline suppresses tran-
scription of MDR1 mRNA, and, over a period of a few days,tional relationships through correlations. Finally, the presence
of MDR1 may mask the contribution of less potent transporters MDR1 disappears from the cells, providing a near-isogenic
model for well-controlled experiments (Aleman et al., 2003).of the same compounds. The somewhat surprising correlation
of compounds with the expression of ABCD1, a peroxisomal Figure 5C shows that the MDR1-expressing cells (MDR1-On)
are 2- to 4-fold more sensitive than are MDR1-Off cells, provid-half-transporter associated with adrenal leukodystrophy (Mos-
ser et al., 1993) (Supplemental Table S6), is probably a conse- ing strong evidence that the increased sensitivity to NSC 73306
is mediated by MDR1 function. Interestingly, NSC 73306 doesquence of the inverse correlation between the expression of
ABCD1 and ABCB1 (r  0.48, see also Figure 1 and Supple- not block MDR1-mediated transport of other molecules (data
not shown), suggesting that it might avoid the well-documentedmental Table S1). Compounds showing inverse correlation with
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Figure 5. Prediction from the NCI-60 data, followed by independent verifi-
cation, that the toxicity of NSC 73306 is potentiated, rather than inhibited,
by expression of ABCB1
A: Scatter plot showing positive correlation (r  0.54; 95% confidence
interval 0.259 to 0.713) of ABCB1 expression with sensitivity of the 60 cell lines
to NSC 73306.
B: Dose-response curves indicating that selected resistant KBV1 cells are
approximately 4-fold more sensitive to NSC 73306 than are the parental KB-
3-1 cells in an MTT assay. Dashed lines indicate the corresponding results in
the presence of 2 M PSC 833, which completely abolished the heightened
sensitivity of KBV1.Figure 4. Prediction from the NCI-60 data of new substrates for ABCC2-MRP2
and ABCC11-MRP8, then validation of the predictions by MTT assay C: Dose-response to NSC 73306 of KB HeLa cells expressing MDR1 under
tetracycline control. Cells were grown in the absence (MDR1-On) or pres-A: Scatter plot showing the correlation (r) of ABCC2 expression with sensitivity
ence (MDR-Off) of 2 g/ml tetracycline for at least seven days beforeof the 60 cells to NSC 641281 (r  0.46; 99.99% two-tailed bootstrap confi-
starting the MTT assay. Cell surface expression and function of MDR1 weredence interval 0.7987 to 0.0440).
verified prior to the assay by staining with anti-MDR1 monoclonal antibodyB: Dose-response curves for treatment of sham-transfected and ABCC2-
(MRK-16) and by a performing a functional assay based on MDR1-controlledtransfected MDCKII dog kidney cells with NSC 641281. The ABCC2-express-
accumulation of the fluorescent dye Calcein (Homolya et al., 1996) (dataing cells showed no signs of toxicity even at maximal concentrations.
not shown). The MTT assay showed an approximately 2-fold higher sensitivityC: Scatter plot showing the correlation (r) of ABCC11 expression with sensitiv-
to NSC 73306 with upregulation of MDR1-P-gp. Values are means 	 SEM ofity of the 60 cells to NSC 671136 (r  0.4; 99.99% two-tailed bootstrap
triplicate measurements.confidence interval 0.6726 to 0.0141). Note: removal of the single, high-
expressing cell line (T47D) from the analysis does not significantly reduce
the observed correlation (r  0.38; 99.99% confidence interval 0.7233
to 0.03915).
D: Dose-response curves for treatment of sham-transfected and ABCC11- in all tested cases by evidence of resistance or sensitivity in
transfected LLC-PK1 non-small cell lung cancer cells with NSC 671136.
cell lines transfected with the appropriate ABC transporters.
Although in some cases the levels of resistance were relatively
low, ample evidence indicates that even low (2- to 4-fold) levels
side effects observed in clinical trials of “classical” MDR1 inhibi- of drug resistance can have a significant impact on the clinical
tors (Kellen, 2003). Possible explanations for the increased (col- efficacy of anticancer treatment (Gottesman et al., 2002). Animal
lateral) sensitivity of otherwise resistant cells include ATP deple- models have also demonstrated decreased responsiveness to
tion (Kabanov et al., 2003) and altered activity of enzymes that chemotherapy in xenografts of a KB line selected for low levels
influence the toxicity of the compound (Bergman et al., 2003). of in vitro resistance (Horton et al., 1988). For many anticancer
The results reported in this section suggest that the pharmaco-
drugs, toxic-to-therapeutic ratios are low and, therefore, even
genomic approach presented here can be exploited to discover
a small increase in cell-based resistance can hamper chemo-such MDR1-potentiated compounds, which may serve as leads
therapy.for development of novel anticancer agents to treat resistant
The importance to cancer therapy of circumventing MDR isdisease. Studies are underway to characterize other positively
evident (Sikic, 1999). Even precisely targeted anticancer drugscorrelated compounds and to elucidate their mechanisms of
are subject to mechanisms of resistance. The real-time RT-PCRaction.
database presented here provides a means to identify (1) ABC
transporters whose expression confers drug resistance, (2)Conclusions
compounds that retain activity in cells that express MDR pro-This work demonstrates correlations between expression of
ABC transporters and response to cytotoxic drugs, confirmed teins, (3) compounds that are exported by MDR proteins, and
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with reference to the mean expression of each ABC transporter across the(4) drugs that exploit hidden vulnerabilities of MDR cells. Here,
60 cell lines.we have summarized some initial conclusions from analyses to
date. More importantly, however, the database will serve for
Drug database
many years as a high-quality “time capsule” that can be mined More than 100,000 chemical compounds have been tested in the NCI-60
by ourselves and others to illuminate additional features of the screen by the Developmental Therapeutics Program. For this study, we
ABC transporters and their complex functional relationships focused on a subset consisting of 118 compounds whose mechanisms of
action are putatively classifiable (Weinstein et al., 1992) and a larger set ofwith other molecules. In particular, these gene expression pro-
1400 compounds that have been tested multiple times and whose screeningfiles will aid studies of the physiological function of the many
data met quality control criteria described elsewhere (Scherf et al., 2000).ABC transporters whose mechanisms remain to be charac-
Both sets are available at http://discover.nci.nih.gov. The two were combinedterized.
to form a joint dataset that included 1429 compounds.
Experimental procedures
Statistical analysis
The statistical analyses were performed using the SAS software package,Purification of RNA
v8.2 (SAS Institute Inc, Cary, NC), and the R package (www.r-project.org).Using the RNeasy kit (Qiagen) according to the manufacturer’s instructions,
Two-dimensional agglomerative hierarchical cluster analysis, with averageas described previously (Scherf et al., 2000), we purified total RNA from
linkage algorithm and distance metric 1r, where r is the Pearson correlationstocks of the cell lines used in the DTP screen. Aliquots of the RNA were
coefficient, was performed using the CIMminer tool (http://discover.nci.nih.stored at 70C. The quality (purity and integrity) of the RNA samples was
gov) to group the 60 cell lines as well as 47 ABC transporters based onassessed using an Agilent 2100 Bioanalyzer with the RNA 6000 NanoLabChip
the expression profiles. The resulting matrix of numbers was displayed inreagent set (Agilent Technologies) and by assessing the ribosomal RNA
clustered image map form (Weinstein et al., 1997) as Figure 1.bands on a native agarose gel. The RNA was quantitated using a spectropho-
To determine quantitatively how well the 47 genes cluster the cell linestometer.
by their tissues of origin, we used a statistical method developed by S.
Lababidi (unpublished data). In that method, the  statistic is used to indicateQuantitative RT-PCR
how well the observed clusters correspond to the nine tissue-of-origin classi-Expression levels of 47 ABC transporters were measured by real-time quanti-
fications. For that calculation, one cell line, UK: NCI-ADR-RES, was excludedtative RT-PCR using the LightCycler RNA Amplification SYBR Green kit
because it did not clearly fit into any of the usual categories.and a LightCycler machine (Roche Biochemicals, Indianapolis, IN). Specific
To identify which genes are, on average, significantly over- or underex-oligonucleotide probes were designed for each of the ABC transporters using
pressed in cells from a given tissue of origin (in comparison with the rest ofDNAStar Primer Select (DNASTAR Inc.), and they were then synthesized at
the cell lines), we used Monte Carlo permutation t tests with 10,000 iterationsLofstrand Laboratories (Gaithersburg, MD). When possible, the amplicons
to compare, for each tissue, the within-tissue mean and the mean over allwere designed to encompass exon-intron boundaries to avoid amplification
of the other tissue types (this approach avoids the assumption of normalityof genomic DNA. The sequence of ABCA13 was not known when we assem-
and is suitable for small sample sizes).bled the PCR primers. Data reporting ABCA13 expression (Supplemental
To narrow down the list of candidates based on correlation of the geneTable S1 at http://www.cancercell.org/cgi/content/full/6/2/129/DC1) were
expression data for 48 ABC transporters and the extended list of 1429 drugtaken from Prades et al., 2002. Since the Syber Green assay detects accumu-
activities measured in 60 cell lines (both centered around zero across thelation of double-stranded DNA, we selected those primers (from a battery
cell lines as well as across the expression values or the drug activities,consisting of about 200 primers) that amplified a single product of the correct
respectively), we calculated the 95% bootstrap confidence intervals of Pear-size. A list of the primers and corresponding gene reference/accession num-
son correlation coefficients for all of the possible relationships (a total ofbers for the ABC proteins is shown in Supplemental Table S7. RT-PCR was
48  1429  68,592 correlation coefficients). The bootstrap confidencecarried out on 150 ng total RNA, in the presence of 250 nM specific primers.
intervals were calculated using the empirical percentiles method with bal-Following reverse transcription (20 min at 55C), the PCR reaction consisted
anced resampling of 10,000 iterations (Chernick, 1999). Balanced resamplingof 45 cycles of denaturation (15 s at 95C), annealing (30 s at 58C), and
forces each observation to appear exactly a number of times equal to theelongation (30 s at 72C). No-template (water) reaction mixtures were pre-
total number of iterations. By bootstrap resampling, we avoided parametricpared as negative controls.
assumptions about the distributions of the variables and incorporated possi-
ble non-normal distributional characteristics. For 10,000 bootstrap iterationsData processing
with 95% confidence interval, the component of resampling error has aDuring the PCR amplification, fluorescence emission was measured and
standard error of no more than 0.002. In recognition of the multiple testingrecorded in real time by the LightCycler. Crossing point values were calcu-
problem we preferred a stringent critical value of p  0.0001. To control thelated, using the LightCycler software package, by the Fit Points analysis
overall false positive rate, we used both a step-down procedure (Westfallmethod, with baseline fluorescence set at 1. The SyberGreen assay mea-
and Young, 1993) and a step-up procedure (Reiner et al., 2003) to adjustsures accumulation of double-stranded products, and the appearance of
for multiple testing of all 47 genes simultaneously. In the Benjamini-Hochbergprimer dimers limits quantitation at high cycle numbers. The specificity of
procedure, the p values are computed in the standard way by permutation,amplified products was verified by melting-curve analysis and agarose gel
assuming that all distributions are exchangeable: the number of values inelectrophoresis (not shown). The raw results were expressed as number of
the permuted data with correlations over a threshold, divided by the numbercycles to reach the crossing point. If the desired product was not detected,
of compounds and by the number of permutations. We calculated the mini-the corresponding value was adjusted to crossing points indicating no ex-
mum FDR (q value) at which each compound would be declared using thepression. To assess the contribution of experimental artifacts, selected cell
step-up procedure for positively correlated test statistics (again true becauselines were assessed in replicate. The average pairwise correlation of replicate
all correlations being compared are computed against the same ABC gene).expression profiles was 0.96. The reproducibility of the measurements was
In this procedure, the first q value for the largest correlation is the Bonferroni-further confirmed by cluster analyses, which showed that replicates clustered
corrected p value for that gene; then further q values are calculated as qj tightly together (data not shown).
max(pj*1429/j, qj1). This procedure limits the expected proportion of falseSince the expression levels of housekeeping genes (glyceraldehyde-3-
positives in the list 1,…j to at most qj.phosphate dehydrogenase [GAPDH], Porphobilinogen Deaminase [PBGD],
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation pro-
tein, and zeta polypeptide [YWHAZ]) were found to be highly variable among Drugs and chemicals
The compounds designated here by NSC numbers were obtained fromthe 60 cell lines (not shown; however, see Vandesompele et al., 2002), they
were not used as controls, and data were normalized with respect to the the Drug Synthesis and Chemistry Branch, Developmental Therapeutics
Program, Division of Cancer Treatment and Diagnosis, National Cancer Insti-mean expression of the transporters (excluding ABCA13). Finally, the values
were mean-centered and multiplied by 1 to indicate expression values tute. Colchicine and dimethyl sulphoxide (DMSO) were purchased from
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Overexpression of a transporter gene in a multidrug-resistant human lungSigma Chemical Co. (St. Louis, MO), and PSC 833 was provided by Novartis
cancer cell line. Science 258, 1650–1654.Pharmaceuticals Corp. (East Hanover, NJ).
Deeley, R.G., and Cole, S.P. (1997). Function, evolution and structure of
Analysis of drug sensitivity multidrug resistance protein (MRP). Semin. Cancer Biol. 8, 193–204.
Cell survival was measured by the MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-
Ellison, G., Klinowska, T., Westwood, R.F., Docter, E., French, T., and Fox,diphenyltetrazolium) assay. Cells were seeded in 100 l medium at a density
J.C. (2002). Further evidence to support the melanocytic origin of MDA-MB-of 5000 cells/well in 96-well plates, and serially diluted drug (with or without
435. Mol. Pathol. 55, 294–299.2 M PSC 833) was added the following day in 100 l medium to give the
indicated final concentration. Cells were then incubated for 72 hr at 37C in Gottesman, M.M., Fojo, T., and Bates, S.E. (2002). Multidrug resistance in
5% CO2, and the MTT assay was performed following the manufacturer’s cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48–58.
instructions (Molecular Probes, Eugene, OR).
Guo, Y., Kotova, E., Chen, Z.S., Lee, K., Hopper-Borge, E., Belinsky, M.G.,
and Kruh, G.D. (2003). MRP8, ATP-binding cassette C11 (ABCC11), is aEfflux assay
cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidinesTrypsinized cells were washed twice in phosphate-buffered saline (PBS).
2
,3
-dideoxycytidine and 9
-(2
-phosphonylmethoxyethyl) adenine. J. Biol.
5  105 cells were preincubated for 5 min at 37C in Iscove’s Modified Chem. 278, 29509–29514.
Dulbecco’s Medium (Quality Biologicals, Gaithersburg, MD) with 0.5% di-
Gupta, R.S., Murray, W., and Gupta, R. (1988). Cross resistance patternmethyl sulphoxide (DMSO), with or without 2 M PSC 833. NSC 634791
towards anticancer drugs of a human carcinoma multidrug-resistant cellwas then added to a final concentration of 1.74 M, and the cells were
line. Br. J. Cancer 58, 441–447.incubated for 10 min at 37C, then sedimented by centrifugation, and resus-
pended in PBS. Green fluorescence intensity was measured using a FacsCal- Homolya, L., Hollo, M., Muller, M., Mechetner, E.B., and Sarkadi, B. (1996).
ibur flow cytometer equipped with a 488 nm argon laser (Becton Dickinson A new method for a quantitative assessment of P-glycoprotein-related multi-
Biosciences, San Jose, CA, USA). Acquisition of events was stopped at drug resistance in tumour cells. Br. J. Cancer 73, 849–855.
10,000.
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